ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SKYE vs LGVN // FORWARD P/E MULTIPLE

Skye Bioscience Inc. (NASDAQ) VS. Longeveron Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: SKYE 1 — LGVN 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SKYE VS. LGVN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SKYE LGVN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 67.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -49.90% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 LGVN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 31.0 31.2 -0.23 LGVN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.8M $5.6M $220.9K SKYE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SKYE REV LGVN REV SKYE GROSS % LGVN GROSS % SKYE FCF LGVN FCF
FY 2025 $0 $1.2M — 67.0% -$43.1M -$18.9M
FY 2024 $0 $2.4M — 78.8% -$26.8M -$14.5M
FY 2023 $0 $709.0K — — -$14.0M -$19.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SKYE // BETA —
LGVN // BETA —